Intrinsiqq
Zentalis Pharmaceuticals, Inc. logo

Zentalis Pharmaceuticals, Inc. Insider Trading

ZNTL

Compare
Last 12 months

Insiders sold 135K and bought nothing on the open market.

78% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Apr 2025.

Net open-market
−135K
0 buys · 4 sales
Under a 10b5-1 plan
78%
of the value sold
Insiders who bought / sold
0 / 3
executives and directors
Last open-market buy
Apr 2025
Apr 30, 2025

Get an email when ZNTL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Aug 14
    William Thurman Walters
    Large holder · bought 4,335,000 at $3.50
    $15.2M
    32% of stake
  • Feb 6 – 1010b5-1 plan
    Vincent Vultaggio
    PAO and PFO · sold 40,224 at avg $2.42
    98K
    22% of stake
  • Feb 6 – 9No plan
    Ingmar Bruns
    Chief Medical Officer · sold 3,297 at avg $2.43
    8K
    9.0% of stake
  • Feb 6 – 9No plan
    Julia Marie Eastland
    CEO & President · sold 8,755 at avg $2.43
    21K
    10.0% of stake
  • Feb 2 – 310b5-1 plan
    Vincent Vultaggio
    PAO and PFO · sold 3,096 at avg $2.54
    8K
    1.6% of stake
  • Dec 31, 2025
    William Thurman Walters
    Large holder · bought 6,459,973 at $1.20
    $7.75M
    92% of stake
  • Dec 15, 2025No plan
    David E. Goel
    Large holder · sold 7,500,000 at $1.33
    $9.97M
    54% of stake
  • Apr 30, 2025
    Scott Dunseth Myers
    Director · bought 21,000 at $1.40
    29K
    8.1% of stake
  • Feb 6, 2025
    Ingmar Bruns
    Chief Medical Officer · bought 20,000 at $2.28
    46K
    120% of stake
  • Feb 3, 2025No plan
    Vincent Vultaggio
    PAO and Interim PFO · sold 2,615 at $1.71
    4K
    1.4% of stake
  • Feb 3, 2025No plan
    Mark Lackner
    Chief Scientific Officer · sold 14,368 at $1.71
    25K
    2.7% of stake
  • Feb 3, 2025No plan
    Andrea Paul
    Chief Legal Officer · sold 13,230 at $1.71
    23K
    1.2% of stake
  • Jan 31, 2025
    Jan Skvarka
    Director · bought 60,000 at $1.72
    103K
    67% of stake
  • Jan 31, 2025
    Luke Nathaniel Walker
    Director · bought 14,200 at $1.76
    25K
    20% of stake
  • Jan 31, 2025
    Julia Marie Eastland
    CEO & President · bought 28,500 at $1.73
    49K
    New position
  • Jan 2, 2025No plan
    Mark Lackner
    Chief Scientific Officer · sold 4,411 at $3.12
    14K
    2.3% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ZNTL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ZNTL

CompareIntrinsic value
ABCLAbCellera Biologics Inc.
$9.69-7.45%16
DERMJourney Medical Corp
$3.32-6.48%15
FBIOFortress Biotech Inc.
$1.90+7.34%59
RMTIRockwell Medical, Inc.
$5.82-7.03%34
LITSLite Strategy, Inc.
$0.80-4.45%25
ENTAEnanta Pharmaceuticals Inc.
$7.62-4.51%25
WVEWave Life Sciences Ltd.
$2.56-5.88%40
OMEROmeros Corporation
$13.21-5.71%28

Held by ETFs

ZNTL is in 5 US ETFs. The largest of them, with ZNTL's weight in each:

Spot a number that looks wrong? Check it in ZNTL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ZNTL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.